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Key Points
• Intragenic PAX5 ampli-
fication defines a novel,
relapse-prone subtype
of B-cell precursor
acute lymphoblastic
leukemia with a poor
outcome.
Introduction
B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is the most common childhood malignancy,
characterized by a wide spectrum of genetic abnormalities, which are used in risk stratification for
treatment.1 PAX5 encodes a transcription factor, which plays a key role in B-cell commitment and
maintenance2 and is frequently (20% to 35%) deleted or mutated in BCP-ALL.3-5 Germline PAX5
mutations also occur in familial ALL.6,7 Furthermore, chromosomal rearrangements involving PAX5 result in
the expression of potentially oncogenic PAX5 fusion genes.8-12 Here we present a subset of patients with
BCP-ALL lacking the major cytogenetic abnormalities (ETV6-RUNX1, BCR-ABL1, and TCF3-PBX1
fusions, high hyperdiploidy, near-haploidy, low hypodiploidy, MLL rearrangements, or intrachromosomal
amplification of chromosome 21)1 with intragenic amplifications of PAX5 (PAX5AMP).
Methods
Patients in this study originated from 15 international study groups. All participating centers obtained
local ethical committee approval and written informed consent in accordance with the Declaration of
Helsinki. Diagnosis of BCP-ALL was confirmed by immunophenotyping, according to standard
criteria. Demographic and clinical details are summarized in supplemental Table 1.
The copy numbers of individual PAX5 exons were determined using the SALSA multiplex ligation-
dependent probe amplification (MLPA) kit P335 IKZF1 (MRC Holland, Amsterdam, The Netherlands),
as previously described (supplemental Methods).13-15 Thirteen PAX5AMP samples were processed on
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SNP6.0 or CytoScan HD arrays (Affymetrix, Santa Clara, CA;
supplemental Methods). Fluorescence in situ hybridization (FISH),
using PAX5 locus-specific probes, was carried out on 26 cases
(supplemental Figures 1 and 2).
Survival analysis considered event-free survival, defined as time to
relapse, and overall survival, defined as time to death, both censored
at last contact. Very early relapse was defined as within 18 months of
diagnosis, early relapse as.18months and#6 months after the end
of treatment, with late relapse defined as occurring .6 months
posttreatment. Survival rates were calculated using the Kaplan-Meier
method and compared using univariate Cox regression models.
All analyses were performed using Intercooled Stata 14.0 (Stata,
College Station, TX).
Results and discussion
PAX5AMP was identified in 79 patients with BCP-ALL, at diagnosis
in 77 cases; only relapse material was available from 2 patients
(Figures 1 and 2A). The amplified region encompassed exons 2 and 5
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Figure 1. MLPA and SNP6.0 profiles of patients
with PAX5AMP. (A) Example of MLPA results using the
P335 IKZF1 MLPA kit. The plot shows the probe ratio for
each target contained in the kit (EBF1, 4 probes; IKZF1,
8 probes; CDKN2A/B, 3 probes; PAX5, 6 probes; ETV6,
6 probes; BTG1, 4 probes; RB1, 5 probes; and the
PAR1 region, CRLF2, CSF2RA, and IL3RA, 1 probe
each). Probe ratio values between 0.75 and 1.3 were
considered to be within the normal range, equivalent to
the normal copy number of 2. Values ,0.75 or .1.3
indicated loss or gain, respectively, and a value ,0.25
indicated biallelic loss. These values correspond to copy
numbers of 1, 3 and 4, and 0, respectively. A value $2.0
corresponds to a copy number of $4 and was inter-
preted as amplification. Approximate copy numbers of
amplified exons ranged from 4 to 22 (median, 5.86).
Ratio values of 1 representative patient (patient 64)
showing amplification of PAX5 encompassing exons 2
and 5, gain of EBF1 consistent with trisomy 5 in this
patient, monoallelic loss of IKZF1, and biallelic loss of
CDKN2A/B. (B) Copy number profiles (log2ratio) of the
PAX5 locus of 8 patients with PAX5AMP processed on
the SNP6.0 array. *In patient 79, PAX5 amplification was
identified at relapse with no material available from
diagnosis. **Patient 60 shows amplification of exon 5
only and gain of exons 1 to 4. (C) Exon and protein
structure of PAX5; the amplified region encodes the
DNA-binding paired domain and the octapeptid motif.
PD, paired DNA-binding domain (amino acids 16-142);
O, octapeptide (aa 179-186); H, homeodomain (aa 228-
254); TA, transactivation domain (aa 304-391); I, in-
hibitory domain (aa 359-391).
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(n 5 68), exon 5 only (n 5 9), or exon 2 only (n 5 2), encoding the
DNA-binding and octapeptide domains (Figure 1). The extent of
PAX5AMP identified by MLPA was confirmed by single-nucleotide
polymorphism arrays (n5 13; Figure 1B; supplemental Figure 3; GEO
database accession number GSE99813). Amplification of the exons
identified by MLPA was validated by quantitative genomic polymerase
chain reaction (n 5 18; data not shown), as previously described.15
Because this MLPA approach did not target PAX5 exons 3 and 4, the
extent of the amplified region in cases with exon 2 or 5 amplification
remains unknown. Several patients with PAX5AMP also presented with
deletions (n 5 8) and gains (3-4 copies; n 5 9) of other PAX5 exons
(Figure 2). The same amplification was present in 9 matched diagnosis
and relapse samples (Figure 2B). FISH analysis excluded the presence
of PAX5 rearrangements and confirmed that the amplification was
located within the PAX5 locus (supplemental Figure 2). Whether
PAX5AMP results in expression of structurally mutant PAX5 proteins or
loss of function remains to be determined.
Although sporadic cases with PAX5AMP have been previously
reported,3,4,16,17 herewe showPAX5AMP to be a recurrent abnormality,
occurring in 52 of 5535 patients from population-based cohorts
(;1% of BCP-ALL and 3% of the B-other subgroups [33 of 1271]
supplemental Table 2). The remaining 27 patients were recruited
individually to this study. Apart from 1 patient case with BCR-ABL1
fusion, PAX5AMP was mutually exclusive of other major risk-stratifying
cytogenetic markers,1 including IGH, PDGFRB/CSF1R, ABL1,
ABL2, JAK2, and ZNF384 rearrangements, among 24 patient cases
tested by FISH (data not shown).
Among the other genes assessed by MLPA, CDKN2A/B loss was
the most common abnormality associated with PAX5AMP (82%),
higher than in other BCP-ALL subgroups.3,18 Gain of EBF1 (26%),
deletion of IKZF1 (13%), and deletion of the PAR1 region resulting
in P2RY8-CRLF2 fusion (10%) were other common alterations,
suggesting a collaborative role in PAX5AMP leukemia development.
Consistent with the MLPA data, chromosomal abnormalities involving
chromosome arm 9p (26%), trisomy 5 (23%), and monosomy
7 (12%) were observed among patients with successful karyotypes
(n 5 57; supplemental Table 3). Notably, trisomy 5 is a rare finding
in BCP-ALL in the absence of high hyperdiploidy. Our previous study
of trisomy 5 as the sole cytogenetic abnormality suggested an
association with poor prognosis.19
The main demographic and clinical features of the 77 patients with
PAX5AMP identified at diagnosis were male predominance (66%), age
.10 years (25%), white blood cell count (WBC) $50 3 109 (39%),
and National Cancer Institute high-risk status (55%). Minimal residual
disease (MRD) data were available for 45 patients. Among ALL2003
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Figure 2. Genetic features of patients with PAX5AMP. (A) Data for the 77 patients with intragenic amplification of PAX5 identified at diagnosis. The copy numbers for
each PAX5 exon and the other genes targeted by the P335 IKZF1 MLPA kit are shown. Cytogenetic results were available for 57 patients, with abnormalities involving the
short arm of chromosome 9, trisomy 5, and monosomy 7 being the most common recurrent chromosomal abnormalities. †In patient 31, the probe ratio values for exons 2 and
5 were just below the cutoff of 2 for $4 copies; because the percentage of blast cells was low at 83.5%, this result was interpreted as amplification. ‡In patient 69, MLPA
showed that exon 2 had a ratio of 2.42 and exon 5 of 1.69; however on the single-nucleotide polymorphism array, exons 2 to 5 were amplified. (B) Data from 9 matched
diagnosis-relapse pairs. *In patient 37, the difference in copy number of the amplified exons between diagnosis and relapse was due to reduced percentage of blasts at
relapse. **P2RY8-CRLF2 fusion assessed by MLPA, FISH, and/or reverse-transcriptase polymerase chain reaction. ***Patient 16 presented with partial trisomy of chromosome
5 as a result of an unbalanced translocation involving chromosomes 1 and 5: 47,XY,der(1)(1qter-1p21::5q?34-5qter),1der(5)(5pter-5q15::1p21-1pter).
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patients with evaluable MRD (n 5 8), 50% were positive at day 28
(.0.01%). Among patients treated in ALL-BFM 2000 with MRD data
(n 5 14), 12 were classified as MRD intermediate risk and 1 each as
high and low risk, whereas all European Organisation for Research and
Treatment of Cancer patients (n 5 10) were intermediate risk, apart
from 1 classified as high risk. From these limited data, we cannot assign
an association between PAX5AMP and MRD.
Among 74 patients with complete remission data available, 73 achieved
complete remission by end of induction; 1 patient died before therapy.
Relapse occurred in 40% (29 of 73) of these patients. The site of re-
lapse, known for 22 patients, was isolated bone marrow (n 5 16),
extramedullary (n5 3), or combined relapse (n5 3). The time to relapse
(median, 2.1 years) was known for 25 patients, with a ratio of very early to
early to late relapse of 9:10:6, classifying 15 (55%) as high risk according
to current criteria.20 Among patients experiencing relapse with sufficiently
long follow-up, 17 (59%) died (relapse, n5 9; infection in remission,
n5 3; unknown, n5 5), and 10 remained alive.3 years postrelapse.
The 5-year EFS and OS rates, evaluable for 74 patients, were 49%
(95% confidence interval [CI], 36%-61%) and 67% (95% CI,
54%-77%), respectively. To identify risk factors, we examined the
effects of age, WBC, National Cancer Institute status, year of di-
agnosis, and presence of additional genetic abnormalities, but only
WBC was significant. Patients with a WBC .50 3 109/L had a
significantly increased risk of death (hazard ratio, 3.48; 95%CI, 1.46-
8.32; P 5 .005). In context, these low survival rates were generated
from patients diagnosed over a 22-year period (1993-2015), treated
according to a wide range of trial protocols, highlighting the need for
prospective studies.
The clinical, genetic, and outcome profiles of patients with PAX5AMP
were distinct from those harboring PAX5 deletions, which occur at
different incidences between BCP-ALL subgroups.3 Although pre-
sent at an increased frequency in high-risk ALL, PAX5 deletions are
not associated with an inferior outcome.21,22 Because the number of
patients with BCP-ALL with distinct PAX5 fusions is limited, their
prognostic relevance remains to be determined.
In conclusion, we have identified a rare subset of patients with
BCP-ALL with PAX5AMP, who share a distinct spectrum of genetic
abnormalities, including high frequencies of CDKN2A/B loss
and trisomy 5. A majority of these patients lack established
cytogenetic abnormalities, suggesting that PAX5AMP may define
a distinct subtype of BCP-ALL. Although several patients
presented with P2RY8-CRLF2 and 1 with BCR-ABL1, both have
been reported as secondary changes occurring alongside primary
genetic abnormalities.3,23,24 Where matched diagnosis and
relapse samples were available, the same amplification was
present at both time points, indicating that PAX5AMP may be an
important driver of leukemogenesis. Because patients with
PAX5AMP showed a high incidence of relapse, we recommend
testing for PAX5AMP in future ALL trials to determine its true
prognostic impact.
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